Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (161-170 of 388) with videos related to

Pageof 39
Sort By:
Cancer|November 17, 2006
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II studySergio Palmeri, Vito Lorusso, Laura Palmeri, et al.
Critical Reviews in Oncology/Hematology|November 8, 2018
Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparisonCamillo Porta, Cezary Szczylik, Roman Casciano, et al.
Journal of Endocrinological Investigation|November 10, 2025
Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitorsNicola Marrano, Mariangela Caporusso, Carlo Ganini, et al.
Clinical Genitourinary Cancer|May 14, 2026
Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell CarcinomaTomer Meirson, Luciano Mutti, Daniel A Goldstein, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2010
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGETThomas E Hutson, Joaquim Bellmunt, Camillo Porta, et al.
Cancer Genomics & Proteomics|June 28, 2019
Intracellular Chloride Ion Channel Protein-1 Expression in Clear Cell Renal Cell CarcinomaAlexandru Nesiu, Anca Maria Cimpean, Raluca Amalia Ceausu, et al.
BJU International|December 17, 2016
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b studyMartin E Gore, Robert J Jones, Alain Ravaud, et al.
European Urology|November 17, 2019
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214Bernard Escudier, Robert J Motzer, Nizar M Tannir, et al.
Cancer Treatment Reviews|October 10, 2017
Adjuvant therapy in renal cell carcinomaFrancesco Massari, Vincenzo Di Nunno, Chiara Ciccarese, et al.
Journal of Nephrology|November 22, 2015
Transplantation of kidneys with tumorsGiovanni M Frascà, Antonia D'Errico, Deborah Malvi, et al.
Pageof 39

Showing results (161-170 of 388) with videos related to

Sort By:
Pageof 39
Cancer|November 17, 2006
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II studySergio Palmeri, Vito Lorusso, Laura Palmeri, et al.
Critical Reviews in Oncology/Hematology|November 8, 2018
Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparisonCamillo Porta, Cezary Szczylik, Roman Casciano, et al.
Journal of Endocrinological Investigation|November 10, 2025
Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitorsNicola Marrano, Mariangela Caporusso, Carlo Ganini, et al.
Clinical Genitourinary Cancer|May 14, 2026
Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell CarcinomaTomer Meirson, Luciano Mutti, Daniel A Goldstein, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2010
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGETThomas E Hutson, Joaquim Bellmunt, Camillo Porta, et al.
Cancer Genomics & Proteomics|June 28, 2019
Intracellular Chloride Ion Channel Protein-1 Expression in Clear Cell Renal Cell CarcinomaAlexandru Nesiu, Anca Maria Cimpean, Raluca Amalia Ceausu, et al.
BJU International|December 17, 2016
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b studyMartin E Gore, Robert J Jones, Alain Ravaud, et al.
European Urology|November 17, 2019
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214Bernard Escudier, Robert J Motzer, Nizar M Tannir, et al.
Cancer Treatment Reviews|October 10, 2017
Adjuvant therapy in renal cell carcinomaFrancesco Massari, Vincenzo Di Nunno, Chiara Ciccarese, et al.
Journal of Nephrology|November 22, 2015
Transplantation of kidneys with tumorsGiovanni M Frascà, Antonia D'Errico, Deborah Malvi, et al.
Pageof 39